Início/NVO

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze NVO in workspace
NVONYSE/health care

Novo Nordisk A/S

$49.28Down-0,20 (-0,40%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Novo Nordisk A/S operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Открытие
49,17
Максимум
49,67
Минимум
48,76
Капитализация
218,05 млрд
P/E
11.82
Максимум за 52 недели
--
Дивиденд
3.640%
Квартальный дивиденд
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. The base case remains conditional on glp-1 competition staying manageable.
Bull case
Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. Fill-finish and active-ingredient investments can improve supply and support broader launches. Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.
Bear case
Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity. Payer restrictions, government negotiation and affordability concerns can reduce realized economics. Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.
Thesis invalidation
Reassess the thesis if rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity.

Key catalysts

  • Obesity-market expansion

    Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population.

  • Manufacturing expansion

    Fill-finish and active-ingredient investments can improve supply and support broader launches.

  • Next-generation pipeline

    Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.

Principal risks

  • GLP-1 competition

    Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity.

  • Pricing and access

    Payer restrictions, government negotiation and affordability concerns can reduce realized economics.

  • Manufacturing execution

    Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.

Latest earnings research

Q1 2026

Novo Nordisk's first-quarter 2026 update focused on global diabetes and obesity demand, expansion of manufacturing capacity and competitive and access dynamics across the GLP-1 market.

Valuation interpretation

  • Long-duration obesity demand supports strategic value, but competitive differentiation and access determine the sustainable growth rate.
  • Capacity investment should be judged by supply reliability and returns after pricing pressure rather than headline demand alone.

Peer research

JNJLLYMRK

Recent news

24/7 Wall St. · 8 часов назад

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Motley Fool · 3 дня назад

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

Motley Fool · 3 дня назад

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

Zacks · 3 дня назад

NVO Rallies 11% in a Month: How Should Investors Play the Stock?

Zacks · 4 дня назад

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Motley Fool · 4 дня назад

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
Financial results for the first three months of 2026Novo Nordisk A/S · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 06/05/2026, 00:00:00

Open original source
Novo Nordisk A/S Investor RelationsNovo Nordisk A/S · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
Novo Nordisk SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 06/05/2026, 00:00:00

Open original source

Continue in the research workspace

Keep NVO in context, run a multi-agent analysis, and monitor thesis changes.

Analyze NVO free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.